Intersect ENT Announces FDA Submission to Seek Expanded Indication of PROPEL Mini Steroid Releasing Implant to Treat Patients With Frontal Sinus Disease MENLO PARK, Calif.—September 29, 2015—Intersect ENT, Inc. (Nasd

First Page		Document Content
Date: 2015-09-29 20:19:21 Medicine Medical equipment Medical technology Propel mometasone furoate implant Intersect ENT RTT Sinus implant Sinusitis Sinus Otorhinolaryngology Frontal sinus Paranasal sinuses		Intersect ENT Announces FDA Submission to Seek Expanded Indication of PROPEL Mini Steroid Releasing Implant to Treat Patients With Frontal Sinus Disease MENLO PARK, Calif.—September 29, 2015—Intersect ENT, Inc. (Nasd Add to Reading List Source URL: propelopens.com Download Document from Source Website File Size: 119,75 KB Share Document on Facebook

	Intersect ENT Announces FDA Submission of NOVA Bioabsorbable Steroid Releasing Implant for Patients with Chronic Sinus Disease MENLO PARK, Calif.—Aug. 1, 2016—Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to DocID: 1sHld - View Document
	PROPEL® (mometasone furoate implant, 370 µg) Instructions For Use CAREFULLY READ ALL INSTRUCTIONS PRIOR TO USE STERILE: STORAGE: DocID: 1qyzI - View Document
	Intersect ENT Announces Publication of PROGRESS Study of Steroid Releasing Implant in Patients With Frontal Sinus Disease Results Demonstrate Clinical Benefits of PROPEL mini in Difficult-to-Treat Patient Population MENL DocID: 1pP5m - View Document
	Intersect ENT Announces Completion of Enrollment in RESOLVE II Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis Company Also Announces Publication of Positive Six-Month Results from RESOLVE Clinica DocID: 1okP8 - View Document
	Intersect ENT Recognized for Gender Diversity by Watermark and UC Davis Company Also Recognized in Deloitte’s 2015 Technology Fast 500 MENLO PARK, Calif., November 17, 2015 – Intersect ENT, Inc. (Nasdaq:XENT), a comp DocID: 1oeqx - View Document